Management of and prognosis with medulloblastoma: Therapy at a crossroads

Archives of Neurology

Volumn 65, Issue 11, 2008, Pages 1419-1424

  Packer, Roger J ^a,b,d,e   Vezina, Gilbert ^a,c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; LOMUSTINE; METHOTREXATE; RETINOIC ACID; VINCRISTINE;

BRAIN RADIATION; CANCER SURVIVAL; DISEASE COURSE; HEARING LOSS; HUMAN; INFECTION; LIVER TOXICITY; MEDULLOBLASTOMA; NEPHROTOXICITY; NEUROPATHY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; REVIEW;

CEREBELLAR NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; MEDULLOBLASTOMA; PROGNOSIS;

EID: 55949132115     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.11.1419     Document Type: Review

References (40)

1. Packer RJ, Cogen P, Vezina G, Rorke LB. Medulloblastoma: clinical and biologic aspects. Neurol Oncol. 1999;1(3):232-250.
2. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1995-1999. Chicago, IL: Central Brain Tumor Registry of the United States; 2005.
3. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415(6870):436-442.
4. MacDonald TJ, Rood B, Santi MR, et al. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist. 2003; 8(2):174-186.
5. Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol. 2003;21(8):1582-1591.
6. Kühl J, Müller HL, Berthold F, et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT/'89. Klin Padiatr. 1998;210(4):227-233.
7. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004;22(6):984-993.
8. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004;63(5):441-449.
9. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202-4208.
10. Oyharcabal-Bourden V, Kalifa C, Gentet JC, et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology study. J Clin Oncol. 2005;23(21):4726-4734.
11. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res. 2001;7(8):2425-2433.
12. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer. 2001;85(5):705-712.
13. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001;29(2):143-152.
14. Grotzer MA, Janss AJ, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol. 2000;18(5):1027-1035.
15. Ellison DW, Onilude OE, Lindsey JC, et al; United Kingdom Children's Cancer Study Group Brain Tumour Committee. Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol. 2005;23(31):7951-7957.
16. Haberler C, Slavc I, Czech T, et al. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur J Cancer. 2006;42(17):2996-3003.
17. Ray A, Ho M, Ma J, et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res. 2004;10(22):7613-7620.
18. Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuroaxis irradiation. J Clin Oncol. 2000;18(16):3004-3011.
19. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial [published correction appears in Lancet Oncol. 2006;7(10):813-820]. Lancet. 2006;7(10):813- 820;17012043.
20. Bailey CC, Gnekow A, Wellek S, et al. Prospective randomized trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol. 1995;25(3):166-178.
21. Bull KS, Spoudeas HA, Yadegarfar G, Kennedy CR; CCLG. Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG). J Clin Oncol. 2007;25(27):4239-4245.
22. Tabori U, Sung L, Hukin J, et al; Canadian Pediatric Brain Tumor Consortium. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. Cancer. 2005;103(9):1874-1880.
23. Carrie C, Lasset C, Blay JY, et al. Medulloblastoma in adults: survival and prognostic factors. Cancer. 1994;74(8):2352-2360.
24. Prados MD, Warnick RE, Wara WM, Larson DA, Lamborn K, Wilson CB. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys. 1995;32(4):1145-1152.
25. Chan AW, Tarbell NJ, Black PM, et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery. 2000;47(3):623-631.
26. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328(24):1725-1731.
27. Geyer JR, Sposto R, Jennings M, et al; Children's Cancer Group. Multi-agent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005;23(30):7621-7631.
28. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352(10):978-986.
29. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg. 1996;85(1):56-65.
30. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol. 2001;19(15):3470-3476.
31. Mulhern RK, Kepner JL, Thomas PR, et al. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. J Clin Oncol. 1989;16(5):1723-1728.
32. Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer. 2003;97(3):663-673.
33. Packer RJ, Gurney JG, Punyko JA, et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: Childhood Cancer Survivor Study. J Clin Oncol. 2003;21(17):3255-3261.
34. Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98(21):1528- 1537.
35. Robertson PL, Muraszko KM, Holmes EJ, et al. Incidence and severity of post-operative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg. 2006;105(6)(suppl):444-451.
36. Read TA, Hegedus B, Wechsler-Reya R, Gutmann DH. The neurobiology of neuro-oncology. Ann Neurol. 2006;60(1):3-11.
37. Raffel C, Jenkins RB, Frederick L, et al. Sporadic medulloblastomas contain PTCH mutation. Cancer Res. 1997;57(5):842-845.
38. Cowan R, Hoban P, Kelsey A, Birch JM, Gattamaneni R, Evans DG. The gene for the nevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer. 1997;76(2):141-145.
39. Paraf F, Jothy S, Van Meir EG. Brain tumor-polyposis syndrome: two genetic diseases? J Clin Oncol. 1997;15(7):2744-2758.
40. Liu J, Guo L, Luo Y, Li JW, Li H. All trans-retinoic acid suppresses in vitro growth and down-regulates LIF gene expression as well as telomerase activity of human medulloblastoma cells. Anticancer Res. 2000;20(4):2659-2664.